Product Description
Piclidenoson is an orally bioavailable, adenosine A3 receptor (A3AR) agonist with potential anti-inflammatory activity. Upon administration, piclidenoson selectively targets, binds to and activates the cell surface-expressed A3AR, thereby activating transduction pathways in which A3AR plays a key role.
Mechanisms of Action: ADORA3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ewopharma AG
Company Location:
Company CEO:
Additonal Commercial Interests: Can-Fite BioPharma
Clinical Description
Countries in Clinic: Bosnia, Bulgaria, Canada, Croatia, Israel, Moldova, Poland, Romania, Serbia
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Psoriasis
Phase 2: COVID-19
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CF101-302PS | P3 |
Not yet recruiting |
Psoriasis |
2027-12-01 |
|
| CF101-301PS | P3 |
Completed |
Psoriasis |
2022-04-28 |
|
| CF101-241COVID-19 | P2 |
Completed |
COVID-19 |
2022-03-06 |
25% |
| 2021-002009-85 | P2 |
Completed |
COVID-19 |
2022-01-06 |